

## COVID-19 Vaccines - FDA Authorizes Pfizer Booster and ACIP Review (Day 2)

- On September 22, 2021 <a href="the-FDA authorized booster doses">the FDA authorized booster doses</a> of the Pfizer-BioNTech COVID-19 vaccine for certain populations. The FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to allow for use of a single booster dose of Comirnaty administered at least six months after completion of the primary series. The eligible population includes:
  - Individuals 65 years of age and older;
  - Individuals 18 through 64 years of age at high risk of severe COVID-19; and
  - Individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19.
- This authorization applies only to the Pfizer-BioNTech COVID-19 vaccine following the initial 2-dose primary series. It does not apply to individuals who received the Moderna or Janssen COVID-19 vaccines. No data exists yet about mixing and matching the available COVID-19 vaccines.
- The <u>Center for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization</u>
   <u>Practices (ACIP)</u> met on September 23, 2021 to discuss the updated EUA and to issue
   recommendations for use.
- The ACIP members evaluated the available data to estimate the risks and benefits of giving a booster
  dose in various populations and situations. Multiple members reaffirmed that the current vaccines,
  including the Pfizer-BioNTech vaccine, are highly effective. Some individuals experience waning
  immunity but not everyone will need a booster dose.
- ACIP stated that a single booster dose of the Pfizer-BioNTech vaccine is recommended in persons:
  - Aged ≥ 65 years, and long-term care facility residence, at least 6 months after the primary series with the Pfizer-BioNTech vaccine under the FDA's EUA.
  - Aged 50 to 64 years with underlying medical conditions, at least 6 months after the primary series with the Pfizer-BioNTech vaccine under the FDA's EUA.
  - Based on individual benefit and risk in individuals who are age 18 to 49 years with underlying medical conditions at least 6 months after the primary series with the Pfizer-BioNTech vaccine under the FDA's EUA.
- The ACIP also discussed use in institutional or occupational settings where risk of COVID-19 is high (homeless shelters, prisons, health care settings), but the majority of members believed the evidence was not sufficient to make a recommendation. An additional meeting to further discuss this issue as well as emerging data is expected in the coming weeks.
- The FDA is reviewing boosters for the Moderna COVID-19 vaccine, but no data is yet available and a
  decision date has not been set.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.